| Entry |
|
|---|
| Name |
EML4-ALK fusion kinase to RAS-ERK signaling pathway
|
|---|
| Definition |
EML4-ALK -> RAS -> RAF -> MEK -> ERK -> CCND1 |
|---|
| Expanded |
(238v1,238v2) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 595 |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00014 | Non-small cell lung cancer |
|
|---|
| Gene |
| 238 | ALK; ALK receptor tyrosine kinase |
| 3265 | HRAS; HRas proto-oncogene, GTPase |
| 3845 | KRAS; KRAS proto-oncogene, GTPase |
| 4893 | NRAS; NRAS proto-oncogene, GTPase |
| 369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
| 673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
| 5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
| 5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
| 5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
| 5594 | MAPK1; mitogen-activated protein kinase 1 |
| 5595 | MAPK3; mitogen-activated protein kinase 3 |
|
|---|
| Variant |
238v1 (EML4-ALK) EML4-ALK fusion
238v2 (EML4-ALK) First generation TKI-resistant ALK1 mutation
|
|---|
| Reference |
|
|---|
| Authors |
Reungwetwattana T, Weroha SJ, Molina JR |
|---|
| Title |
Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Roskoski R Jr |
|---|
| Title |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Janne PA, Gray N, Settleman J |
|---|
| Title |
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Solomon B, Wilner KD, Shaw AT |
|---|
| Title |
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
